Feasibility Open Label Study Evaluating The Use Of Process-Instructed Self Neuro-Modulation (PRISM) For Post-Traumatic Stress Disorder

Inclusion Criteria: * Adults ages 18-65 years * Able to provide signed informed consent * Any gender * Diagnosis of PTSD as established by DSM-V * 1 to 15 years since index trauma * Taking a stable dose of SSRI antidepressants for at least 3 months OR un-medicated for at least 2 months * Normal or corrected-to-normal vision * Normal or corrected-to-normal hearing * No intention of changing medication or psychotherapy for the duration of the study at the time of recruitment Exclusion Criteria: * Concurrent substance abuse * Use of any prescribed benzodiazepine * Lifetime bipolar disorder, psychotic disorder, autism, mental retardation. Comorbid mood and anxiety disorders will be permitted if they are not the primary focus of clinical attention * Active suicidality within past year, or history of suicide attempt in past 2 years * Any history of severe past drug dependence (i.e., a focus of clinical attention or a cause of substantial social or occupational difficulty) * Any unstable medical or neurological condition * Any history of brain surgery, of penetrating, neurovascular, infectious, or other major brain injury, of epilepsy, or of other major neurological abnormality (including a history of traumatic brain injury \[TBI\] with loss of consciousness for more than 24 hours or posttraumatic amnesia for more than 7 days) * Any psychotropic medication other than a stable dose of selective serotonin reuptake inhibitors (SSRIs) * Any change in accepted psychotropic medication within the past 2 months * Recent initiation (within the past 3 months) of cognitive-behavioral therapy or any evidence-based PTSD psychotherapy (Cognitive Processing Therapy \[CPT\], Prolonged Exposure \[PE\], Eye Movement -Desensitization and Reprocessing \[EMDR\]); continuation of established maintenance supportive therapy will be permitted * Significant hearing loss or severe sensory impairment * Enrollment in another research study testing an experimental, clinical, or behavioral intervention intended to affect symptoms initiated within the last 2 months, or intended enrollment within the next 2.5 months